28 June 2018 
EMA/CHMP/324506/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Veyvondi 
vonicog alfa 
On 28 June 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Veyvondi, 
intended for the treatment of von Willebrand disease. Veyvondi was designated as an orphan medicinal 
product on 26 November 2010. The applicant for this medicinal product is Baxalta Innovations GmbH. 
Veyvondi will be available as a powder and solvent for solution for injection (650 IU and 1300 IU). The 
active substance of Veyvondi is vonicog alfa, a recombinant human von Willebrand factor which behaves 
in the same way as endogenous von Willebrand factor (ATC code: B02BD10). 
The benefits with Veyvondi are its ability to re-establish platelet adhesion to the endothelium at the site 
of blood vessel damage and to correct associated factor VIII deficiency. The most common side effects 
are dizziness, vertigo, dysgeusia, tremor, tachycardia, deep venous thrombosis, hypertension, hot flush, 
vomiting, nausea, generalised pruritus, chest discomfort, infusion site paraesthesia, electrocardiogram T 
wave inversion and increased heart rate.  
The full indication is:  
"Veyvondi is indicated in adults (age 18 and older) with von Willebrand disease (VWD), when 
desmopressin (DDAVP) treatment alone is ineffective or not indicated for the:  
• 
• 
Treatment of haemorrhage and surgical bleeding 
Prevention of surgical bleeding. 
Veyvondi should not be used in the treatment of Haemophilia A." 
It is proposed that Veyvondi be prescribed by physicians experienced in the treatment of haemostatic 
disorders.  
Detailed recommendations for the use of this product will be described in the summary of product 
characteristics (SmPC), which will be published in the European public assessment report (EPAR) and 
made available in all official European Union languages after the marketing authorisation has been 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
granted by the European Commission. 
Veyvondi  
EMA/CHMP/324506/2018 
Page 2/2 
 
  
  
